GSK shares fell after the U.K. drugmaker said it would stop working on an experimental treatment for chronic cough after ...

GSK drops camlipixant's refractory chronic cough program after mixed phase III results, but the drug remains in a phase IIb ...

Three years after buying Bellus Health and its chronic cough candidate camlipixant for around $2 billion, GSK is abandoning ...

Experts say that along with Covid-19, there is also a rise in influenza, adenoviruses, and rhinoviruses, which has led to a ...

GSK (GSK) stock slips as the company discontinues a cough therapy added from its $2B Bellus Health acquisition following a ...

Shares in GSK fell sharply on Friday after the pharma titan announced it was stopping the development of a refractory chronic ...

GSK plc provides an update on the CALM-1 and CALM-2 phase III clinical trials, which assessed the efficacy and safety of two doses of camlipixant (a P2X3 receptor antagonist) in adults with refractory ...

After GSK (GSK) announced it would discontinue a chronic cough therapy following a late-stage trial failure, Trevi ...

GSK plc is halting work with camlipixant, a P2X3 receptor antagonist, in adults with refractory chronic cough (RCC) after reporting mixed results from the Calm-1 and Calm-2 phase III trials. The first ...

GSK has ended development of camlipixant in chronic cough after delivering mixed phase 3 data, dealing a major blow to a potential blockbuster that analysts saw as the key 2026 catalyst for the ...

Actor Sam Neill's death from pneumonia has renewed attention on this lung infection. Early symptoms often resemble a cold or flu, making them easily dismissed. Older adults and those with underlying ...

Fever is a defence mechanism of the body against infection which may persist for more than three days during viral illnesses ...